FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	$D \subset$	205/10
vasiiiiiqtuii,	D.C.	20349

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and	Address of R	eporting Person*				2. Issue	er Naı	me <b>and</b> Ticke	r or Tradin	g Sy	mbol	10 10		tionship of Re		erson(	s) to Issuer		
Ramaswamy Vivek					<u> </u>	Roivant Sciences Ltd. [ ROIV ]							Crieck	heck all applicable)  Director X 10% Owner				ner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 09/27/2023								Officer (give title Other (specify below) below)						
PO BOX 20860					_ [	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
(Street)	urie Oi	T	42220										Form filed by More than One Reporting Person						
COLUMB	BUS OI		43220		_[	Rule 10b5-1(c) Transaction Indication													
(City)	(St	ate)	(Zip)			Check this box to indicate that a transaction was made pursuant to a cont affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							a contract, instr 0.	act, instruction or written plan that is intended to satisfy the					
			Table I - N	lon-D	eriva	ative	Sec	urities Ac	quired,	Dis	posed of	, or Ben	eficially O	wned					
Date			Date			2A. Deemed Execution Date, if any				4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			5. Amount of Securities Beneficially O		Form:		. Nature of ndirect		
(mon				in buy, reury		(Month/Day/Year)		Code	v	Amount	(A) or (D)	Price	Following F Transaction (Instr. 3 and	Reported n(s)			Ownership (Instr. 4)		
Common Shares 09/2'					27/20	2023			M <sup>(1)(2)(3)</sup>		119,534 A		(1)(2)(3)	54,850,	057 <sup>(7)</sup>		D		
Common Shares 09/28/				28/20	2023		J <sup>(4)</sup>		61,947 D		\$12.67(5)	54,788,	788,110 <sup>(7)</sup>		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate,		saction e (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date Securities (Month/Day/Year) Securities		. Title and Amount of ecurities Underlying erivative Security nstr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Capped Value Appreciation Rights	(1)(2)(6)	09/27/2023			M			203,798 <sup>(1)(2)</sup>	(1)(2)		03/31/2026	Common Shares	97,031(1)(2)	\$6.4(1)(2)(6)	7,744,31	14 <sup>(6)</sup>	D		
Capped Value Appreciation Rights	(1)(3)	09/27/2023			M			251,539 <sup>(1)(3)</sup>	(1)(3)		03/31/2026	Common Shares	22,503(1)(3)	\$11.5 <sup>(1)(3)</sup>	11,822,	.307	D		

## **Explanation of Responses:**

- 1. Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at \$12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").
- 2. On September 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 203,798 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 97,031 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023.
- 3. On September 27, 2023, the hurdle price applicable to 251,539 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 22,503 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023.
- 4. Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's "sell to cover" policy and does not represent a discretionary sale by the reporting person.
- 5. The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.25 to \$13.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
- 6. In the event the fair market value of a Common Share is less than \$9.20 per share as of the relevant date of determination (the "knock-in condition"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs.
- 7. Includes an award of restricted stock covering Common Shares that is fully vested.

By: /s/ Steve Roberts, as 09/29/2023 Attorney-in-Fact for Vivek Ramaswamy

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.